Articles by Yvette C. Terrie
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
AI-powered TIL analysis may predict pCR and survival outcomes in HR+/HER2– breast cancer treated with neoadjuvant chemo.
Imlunestrant improved quality of life and physical function in patients with ER+/HER2– breast cancer in the EMBER-3 trial.
T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations.
Inavolisib + palbociclib + fulvestrant extends OS and delays chemo in PIK3CA-mutant HR+/HER2- advanced breast cancer.
T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events.
Real-world data reveal varying efficacy of CDK4/6 inhibitors in HR+/HER2- aBC, supporting personalized treatment choices.
Darolutamide did not meet the clinical benefit endpoint in AR-positive TNBC, per findings from the phase II START trial.
Adding atezolizumab to chemotherapy did not result in clinical benefit in patients with triple-negative breast cancer.
Study finds somatic differences and lower PI3K inhibitor use in Black vs White patients with metastatic breast cancer.
Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.